Cargando…

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Caputo, Emilia, Miceli, Roberta, Motti, Maria L, Taté, Rosarita, Fratangelo, Federica, Botti, Gerardo, Mozzillo, Nicola, Carriero, Maria V, Cavalcanti, Ernesta, Palmieri, Giuseppe, Ciliberto, Gennaro, Pirozzi, Giuseppe, Ascierto, Paolo A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315274/ http://dx.doi.org/10.1186/1479-5876-13-S1-P1

Ejemplares similares

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
por: Caputo, Emilia, et al.
Publicado: (2014)

AurkA nuclear localization is promoted by TPX2 and counteracted by protein degradation
por: Asteriti, Italia Anna, et al.
Publicado: (2023)

Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells
por: Fratangelo, Federica, et al.
Publicado: (2018)

AurkA controls self-renewal of breast cancer-initiating cells promoting wnt3a stabilization through suppression of miR-128
por: Eterno, V., et al.
Publicado: (2016)

Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors
por: Marusiak, Anna A., et al.
Publicado: (2014)

Phenotype characterization of human melanoma cells resistant to dabrafenib
por: Cordaro, Fabiola Gilda, et al.
Publicado: (2017)

Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells
por: Ragone, Concetta, et al.
Publicado: (2017)

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
por: Atefi, Mohammad, et al.
Publicado: (2015)

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
por: Schreck, Karisa C., et al.
Publicado: (2019)

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
por: Lai, You-Liang, et al.
Publicado: (2022)

PLX8394, a RAF inhibitor, inhibits enterovirus 71 replication by blocking RAF/MEK/ERK signaling
por: Wu, Chengyuan, et al.
Publicado: (2023)

Silencing of AURKA augments the antitumor efficacy of the AURKA inhibitor MLN8237 on neuroblastoma cells
por: Yang, Yan, et al.
Publicado: (2020)

Do BRAF inhibitors select for populations with different disease progression kinetics?
por: Ascierto, Paolo Antonio, et al.
Publicado: (2013)

Controversial Role of Kisspeptins/KiSS-1R Signaling System in Tumor Development
por: Fratangelo, Federica, et al.
Publicado: (2018)

Activation of the ErbB3-AKT axis promotes melanoma cell survival and proliferation in response to RAF/MEK inhibition
por: Fattore, Luigi, et al.
Publicado: (2014)

ErbB3 plays a key role in the early phase of establishment of resistance to BRAF and/or MEK inhibitors
por: Fattore, Luigi, et al.
Publicado: (2015)

STAT3 inhibitor sensitized KRAS-mutant lung cancers to RAF inhibitor by activating MEK/ERK signaling pathway
por: Wang, Zhenlin, et al.
Publicado: (2019)

RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors
por: Yuan, Xi, et al.
Publicado: (2020)

“RAF” neighborhood: Protein–protein interaction in the Raf/Mek/Erk pathway
por: Cseh, Botond, et al.
Publicado: (2014)

MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors
por: Motti, Maria Letizia, et al.
Publicado: (2020)

RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition
por: Jin, Ting, et al.
Publicado: (2017)

Synergistic effect of the inhibitors of RAF/MEK and AXL on KRAS‐mutated ovarian cancer cells with high AXL expression
por: Umemura, Shiori, et al.
Publicado: (2020)

GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma Cells
por: Booth, Laurence, et al.
Publicado: (2021)

Neoadjuvant B-RAF and MEK Inhibitor Targeted Therapy for Adult Papillary Craniopharyngiomas: A New Treatment Paradigm
por: Calvanese, Francesco, et al.
Publicado: (2022)

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma
por: Daponte, Antonio, et al.
Publicado: (2013)

Resistance to RAF inhibitors revisited
por: Hartsough, Edward, et al.
Publicado: (2013)

Conferring specificity on the ubiquitous Raf/MEK signalling pathway
por: O'Neill, E, et al.
Publicado: (2004)

Growth Inhibitory Signaling of the Raf/MEK/ERK Pathway
por: Wu, Pui-Kei, et al.
Publicado: (2020)

Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways
por: García-Echeverría, Carlos
Publicado: (2008)

A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors
por: Raimondi, Vincenzo, et al.
Publicado: (2022)

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
por: Chappell, William H., et al.
Publicado: (2011)

Dual-Inhibitors of N-Myc and AURKA as Potential Therapy for Neuroendocrine Prostate Cancer
por: Ton, Anh-Tien, et al.
Publicado: (2020)

The Dual RAF/MEK Inhibitor CH5126766/RO5126766 May Be a Potential Therapy for RAS-Mutated Tumor Cells
por: Wada, Makoto, et al.
Publicado: (2014)

Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells
por: Shingu, Takashi, et al.
Publicado: (2016)

Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3‐Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations
por: Bardia, Aditya, et al.
Publicado: (2019)

Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies
por: Fattore, Luigi, et al.
Publicado: (2013)

Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma
por: Fattore, Luigi, et al.
Publicado: (2015)

Mechanisms of resistance to RAF inhibitors in melanoma
por: Aplin, Andrew E., et al.
Publicado: (2011)

The mechanism of activation of MEK1 by B-Raf and KSR1
por: Maloney, Ryan C., et al.
Publicado: (2022)

Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a (V600E)BRAF inhibitor): a case report
por: Simeone, Ester, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_03kujplklm8sgdk2fcfaa7fhbl